Laboratorios ROVI informed the National Securities Market Commission (CNMV) this Wednesday that the purchase agreement entered into between its subsidiary ROIS Phoenix Inc. and Bristol Myers Squibb (BMS) for the acquisition of a pharmaceutical manufacturing plant in Phoenix, Arizona (United States), has been completed.
As part of the transaction, the group has entered into a toll manufacturing agreement governing the terms under which ROIS Phoenix will continue to manufacture for BMS at the plant.
This transaction represents a strategic acquisition for ROVI and a key milestone towards achieving its vision of becoming one of the leading global manufacturers of high-value‑added injectables (pre-filled syringes, cartridges and vials).
Find here the information submitted to the CNMV earlier today.